Showing 1 - 10 results of 10 for search 'Raymond T. Bartus', query time: 0.03s Refine Results
  1. 1
    Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest

    Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest by Raymond T. Bartus

    Published 2012-11-01
    Get full text
    Article
  2. 2
    Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned?

    Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned? by Raymond T. Bartus, Eugene M. Johnson, Jr.

    Published 2017-01-01
    Get full text
    Article
  3. 3
    Injection of Chemotherapeutic Microspheres and Glioma III: Parameters to Optimize Efficacy

    Injection of Chemotherapeutic Microspheres and Glioma III: Parameters to Optimize Efficacy by Dwaine F. Emerich, Shelley R. Winn, Raymond T. Bartus Ph.D.

    Published 2002-01-01
    Get full text
    Article
  4. 4
    β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)

    β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS) by Raymond T. Bartus, Alexandre Bétourné, Anthony Basile, Bethany L. Peterson, Jonathan Glass, Nicholas M. Boulis

    Published 2016-01-01
    Get full text
    Article
  5. 5
    Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease

    Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease by Shilpa Ramaswamy, Jodi L. McBride, Christopher D. Herzog, Eugene Brandon, Mehdi Gasmi, Raymond T. Bartus, Jeffrey H. Kordower

    Published 2007-05-01
    Get full text
    Article
  6. 6
    Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

    Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease by Raymond T. Bartus, Lamar Brown, Alistair Wilson, Brian Kruegel, Joao Siffert, Eugene M. Johnson, Jr., Jeffrey H. Kordower, Christopher D. Herzog

    Published 2011-10-01
    Get full text
    Article
  7. 7
    Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

    Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120) by Christopher D. Herzog, Lamar Brown, Brian R. Kruegel, Alistair Wilson, Malú G. Tansey, Fred H. Gage, Eugene M. Johnson, Jr., Raymond T. Bartus

    Published 2013-10-01
    Get full text
    Article
  8. 8
    Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease

    Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease by Shilpa Ramaswamy, Jodi L. McBride, Ina Han, Elizabeth M. Berry-Kravis, Lili Zhou, Christopher D. Herzog, Mehdi Gasmi, Raymond T. Bartus, Jeffrey H. Kordower

    Published 2009-04-01
    Get full text
    Article
  9. 9
    AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

    AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease by Mehdi Gasmi, Eugene P. Brandon, Christopher D. Herzog, Alistair Wilson, Kathie M. Bishop, Eva K. Hofer, Justine J. Cunningham, Marie A. Printz, Jeffrey H. Kordower, Raymond T. Bartus

    Published 2007-07-01
    Get full text
    Article
  10. 10
    Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS

    Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS by Colin K. Franz, Thais Federici, Jun Yang, Carey Backus, Sang Su Oh, Qingshan Teng, Erin Carlton, Kathie M. Bishop, Mehdi Gasmi, Raymond T. Bartus, Eva L. Feldman, Nicholas M. Boulis

    Published 2009-03-01
    Get full text
    Article

Search Tools: